BioTissue Ocular

Home
United States
Miami, FL
BioTissue Ocular

Directions Website

We develop innovative Amniotic Membrane products for the management of ocular surface diseases.

BioTissue® is the leader in regenerative biologic therapies and ocular hygiene solutions, helping eye care professionals heal ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis dry eye, pterygium and dry eye.

10/26/2026

There’s a reason we call it the BioTissue Experience.

From meaningful conversations to shared perspectives, the BioTissue Experience was all about connecting with physicians who share our commitment to advancing ocular surface care.

Thank you to everyone who joined us.

10/21/2026

At AECOS, our President and CEO, Ted Davis, reintroduced BioTissue® through the lens of our Ocular First strategy and what that focus means for our future.

With over 25+ years of industry leading innovation, 440+ peer-reviewed publications, and more than 1.2 million clinical applications, we’re building on a strong foundation of science, experience, and leadership in ocular surface care.

And with innovations like CAM360 AmnioGraft™, we’re continuing to move that legacy forward.

10/20/2026

Big conversations in The Big Easy.

From ASOPRS to Academy of Ophthalmology, we connected with the eye care physicians discussing the use of Cryopreserved Amniotic Membrane and our portfolio of products across Prokera®, CAM360 AmnioGraft™, AmnioGraft®, and AmnioGuard®.

Thank you to everyone who spent time with our BioTissue® team.

Still have questions? Connect with us via our website: https://brnw.ch/21x6yiT

10/19/2026

We’ve got our eyes on four words. 👀

How many did you find?

1. Mead OG, Tighe S, Tseng SCG. Amniotic membrane transplantation for managing dry eye and neurotrophic keratitis. Taiwan J Ophthalmol. 2020 Mar 4;10(1):13-21.
2. Data on file.
3. John, T, Tighe, S, Sheha, H. et al. Corneal Nerve Regeneration after Self-Retained Cryopreserved Amniotic Membrane in Dry Eye Disease. J Ophthalmol. 2017;2017:6404918. https://brnw.ch/21x6wBX

10/16/2026

Defining the standard with an average of 1 to 1.1 CAM placements reported across published studies evaluating CAM for the treatment of dry eye disease.¹⁻²

BioTissue® supports single placement, with additional placements only when medically necessary based on the treating physician’s assessment.

Grounded in published clinical evidence, CAM continues to support physicians in the management of ocular surface disease.

Learn more about BioTissue’s cryopreserved amniotic membrane products: https://brnw.ch/21x6tcX

1. McDonald, M, Janik, SB, Bowden, FW. et al. Association of Treatment Duration and Clinical Outcomes in Dry Eye Treatment with Sutureless Cryopreserved Amniotic Membrane. Clin Ophthalmol. 2023;Sep 12:17:2697- 2703.

2. John T, Tighe S, Sheha H, Hamrah P, Salem ZM, Cheng AMS, Wang MX, Rock ND. Corneal nerve regeneration after self-retained cryopreserved amniotic membrane in dry eye disease. J Ophthalmol. 2017;2017:6404918. doi:10.1155/2017/6404918.

10/15/2026

BioTissue® is proud to be recognized on the 2026 Fortune Best Workplaces in BioPharma™ list, ranking #21!

This recognition reflects the dedication, collaboration, and commitment of our employees who make BioTissue a great place to work every day.

We're grateful to our team for fostering a culture built on teamwork, innovation, and a shared passion for making a difference.

Read the full press release to learn more: https://brnw.ch/21x6roS

10/09/2026

New clinical research from BioTissue is being presented at AAO 2026.

The research will be presented at the American Academy of Ophthalmology (AAO) Annual Meeting.

Read the full press release to learn more: https://brnw.ch/21x6isg

10/07/2026

Please join us in welcoming Ryan Brown to BioTissue® as our new Senior Director, Professional Relations & KOL Development!

In his new role, Ryan will focus on strengthening our KOL network, deepening relationships with influential clinicians, and supporting continued advocacy and education across eye care.

We’re excited to have Ryan on the team and look forward to the experience and perspective he brings to BioTissue.

10/06/2026

Join us October 10–12 to connect with the BioTissue® team and experience our ocular portfolio in action.

Hear from our in-booth experts and your peers, then get hands-on in our wet lab with CAM360 AmnioGraft™, Prokera®, AmnioGraft® & AmnioGuard®.

Come with questions. Leave with practical insights you can bring back to your patients and practice.

📍 New Orleans | October 10–12

We’ll see you at AAO!

10/05/2026

We enjoyed another great Academy meeting connecting with and supporting the optometric community!

Thank you to everyone who stopped by to talk ocular surface care and how CAM360 AmnioGraft™ & Prokera® can support your patients.

Missed our team at AAO or still have questions? Connect with us: https://brnw.ch/21x6bxY

Address

7300 Corporate Center Drive, Suite 700
Miami, FL
33126

Website

http://www.biotissue.com/products/BioTissue-ocular/

Alerts

Be the first to know and let us send you an email when BioTissue Ocular posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your practice to be the top-listed clinic in Miami?